Rituximab Raises Inflammatory Bowel Disease Risk in MS
Rituximab ibd risk in sclerosis patients was observed in a Swedish cohort, with an incidence of 110 per 100,000 person-years, far above other therapies.
Featured Stories
All Stories →
MedPage Today journalists win awards for deep healthcare reporting
MedPage Today journalists win awards for deep healthcare reporting on digital health tools, clinical trials, and new treatments driving U.S.…
Study Finds Child Hepatitis B Exposure From Household
Study finds child hepatitis B exposure often comes from someone other than their mother in the household.
Long wait for intestine transplant highlights system’s delays
Katherine Screws waited three years for an intestine transplant at UCLA Health, despite initial estimates of a six-month wait, exposing…
Diet Links
More →
BP Trends
More →Monitor Picks
More →
Stress Checks
More →
Drug Doses
More →
Popular Posts
Refresh ↺Central Park Crash Sparks Safety Concerns
Central Park crash sparks safety concerns after runner hit by e-bike rider in New York City's popular running route.
Kaduna Tackles River Blindness Treatment Access Challenges
Kaduna addresses river blindness treatment access challenges, focusing on reaching all eligible residents for effective care.
Federal Rule Hinders Opioid Fight
Federal rules hinder opioid fight efforts, posing challenges to addressing overdose incidents with harmful substances like N-methylclonazepam.
Brain Development Peaks in Early Thirties
Brain development peaks in early thirties with significant changes in structural connectivity, according to a recent study on brain network…
Eating Disorders And Body Image: The Universal Link
Body image is something that everyone, one way or another, has to deal with in their lifetime. When you look…
Breakthrough pancreatic cancer drug doubles survival in late-stage patients
FDA-approved daraxonrasib may double survival for late-stage pancreatic cancer patients after chemotherapy failure, per University of Chicago trial data.